33 completed, 7 unknown, 6 terminated, 5 active not recruiting. 58 Phase 1, 18 Phase 2.
Follow Chorea: new trials by email Literature Review of Chorea trials Research Report on Chorea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease SRP-1005, Placebo - Huntington's Disease | Phase 1 | Recruiting | Sarepta Therapeutics, Inc. | 32 | 2026-05-12 | 2026-10-19 |
| Mass Balance Study of [14C] LPM3770164 in Healthy Participants [14C] LPM3770164 - Huntington Disease | Phase 1 | Not yet recruiting | Luye Pharma Group Ltd. | 8 | 2026-04-30 | 2026-04-08 |
| Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease hNSC-01 - Huntington Disease | Phase 1 / Phase 2 | Recruiting | Leslie Thompson | 21 | 2026-04-06 | 2026-04-13 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease RG6496, Placebo - Huntington's Disease | Phase 1 | Active not recruiting | Hoffmann-La Roche | 3 | 2025-11-19 | 2026-09-02 |
| A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease SPK-10001, Placebo Surgery Control - Huntington Disease | Phase 1 / Phase 2 | Recruiting | Hoffmann-La Roche | 53 | 2025-02-21 | 2026-05-05 |
| A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease. ER2001 intravenous injection, Placebo - Huntington Disease | Phase 1 / Phase 2 | Active not recruiting | ExoRNA Bioscience | 27 | 2025-02-11 | 2026-01-14 |
| A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease ALN-HTT02, Placebo - Huntington's Disease | Phase 1 | Recruiting | Alnylam Pharmaceuticals | 66 | 2024-10-14 | 2026-10-15 |
| Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets LPM3770164 sustained release tablet - Huntington Disease, Tardive Dyskinesia | Phase 1 | Completed | Luye Pharma Group Ltd. | 16 | 2024-07-31 | 2024-12-12 |
| Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects LPM3770164 sustained release tablet, LPM3770164 sustained release tablet simulant - Tardive Dyskinesia, Huntington Disease | Phase 1 | Completed | Luye Pharma Group Ltd. | 40 | 2023-12-19 | 2024-12-12 |
| A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD VO659 - Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3 | Phase 1 / Phase 2 | Recruiting | Vico Therapeutics B. V. | 68 | 2023-02-14 | 2026-08-19 |
| A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease AB-1001 Gene Therapy - Huntington Disease | Phase 1 / Phase 2 | Active not recruiting | AskBio France, SAS, a subsidiary of AskBio Inc. | 5 | 2022-10-12 | 2026-05-14 |
| A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects LPM3770164 sustained release tablet, LPM3770164 sustained release tablet simulant - Huntington Disease, Tardive Dyskinesia | Phase 1 | Completed | Luye Pharma Group Ltd. | 104 | 2022-02-25 | 2024-01-29 |
| Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated with HD Deutetrabenazine Oral Tablet [Austedo], Placebo oral tablet - Huntington Disease | Phase 1 | Terminated | Fundacion Huntington Puerto Rico | 36 | 2022-01-21 | 2025-02-27 |
| Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease intra-striatal rAAV5-miHTT - Huntington Disease | Phase 1 / Phase 2 | Active not recruiting | UniQure Biopharma B.V. | 14 | 2021-10-07 | 2025-03-10 |
| Study of WVE-003 in Patients With Huntington's Disease SAD: 30mg WVE-003, SAD: 60mg WVE-003, SAD: 90mg WVE-003 - Huntington Disease | Phase 1 / Phase 2 | Completed | Wave Life Sciences USA, Inc. | 47 | 2021-09-06 | 2025-08-12 |
| Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease Intraparenchymal rAAV1 - (mi)RNA HTT - Huntington Disease | Phase 1 | Withdrawn | Voyager Therapeutics | 2021-07-30 | 2021-08-16 | |
| Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease WVE-120101 - Huntington Disease | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 27 | 2020-04-13 | 2022-02-09 |
| Symptomatic Therapy for Patients With Huntington's Disease Haloperidol 2Mg Tab, Risperidone 1Mg Tab, Zoloft 50Mg Tablet - Huntington Disease | Phase 1 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 60 | 2020-03-12 | 2021-04-02 |
| Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease WVE-120102 - Huntington Disease | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 36 | 2019-09-24 | 2022-02-09 |
| Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease intra-striatal rAAV5-miHTT, Imitation (sham) surgery - Huntington's Disease | Phase 1 / Phase 2 | Active not recruiting | UniQure Biopharma B.V. | 43 | 2019-09-06 | 2025-10-21 |
Showing 20 of 58. Sign in to see all of them.
Huntington Disease (57) · Alzheimer Disease (10) · Movement Disorders (5) · Mental Disorders (4) · Neurodegenerative Diseases (4) · Brain Diseases (3) · Central Nervous System Diseases (3) · Cognition Disorders (3) · Genetic Diseases, Inborn (3) · Nervous System Diseases (3) · Tardive Dyskinesia (3) · Basal Ganglia Diseases (2) · Dementia (2) · Dyskinesias (2)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (57) · Dyskinesias (56) · Neurocognitive Disorders (56) · Basal Ganglia Diseases (55) · Central Nervous System Diseases (55) · Dementia (55) · Heredodegenerative Disorders, Nervous System (55) · Nervous System Diseases (55) · Brain Diseases (54) · Cognition Disorders (54) · Genetic Diseases, Inborn (54) · Mental Disorders (53) · Movement Disorders (53) · Neurodegenerative Diseases (53)
latrepirdine (8) · 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide (3) · 5-(5-((2,4-dimethylthiazol-5-yl)methyl)-1,3,4-oxadiazol-2-yl)-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo(3,4-b)pyridin-4-amine (2) · deutetrabenazine (2) · 7-(2-(4-(2-fluoro-4-iodophenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidin-5-amine (1) · Alprazolam (1) · CKD-504 (1) · Cell- and Tissue-Based Therapy (1) · Creatine (1) · Dextromethorphan (1) · Digoxin (1) · Fluorine-18 (1) · HTT(RX) (1) · Haloperidol (1) · Histone Deacetylase Inhibitors (1)
Pfizer (9) · Wave Life Sciences USA, Inc. (5) · Hoffmann-La Roche (4) · Luye Pharma Group Ltd. (4) · Siena Biotech S.p.A. (3) · GlaxoSmithKline (2) · Institute for Neurodegenerative Disorders (2) · UniQure Biopharma B.V. (2) · University of Rochester (2) · Alnylam Pharmaceuticals (1) · AskBio France, SAS, a subsidiary of AskBio Inc. (1) · Azidus Brasil (1) · Chaitanya Hospital, Pune (1) · Chong Kun Dang Pharmaceutical (1) · ExoRNA Bioscience (1)
United States (25) · United Kingdom (15) · Germany (12) · Canada (10) · Australia (7) · France (7) · China (6) · Denmark (6) · Poland (6) · Netherlands (4) · Spain (3) · New Zealand (2) · Argentina (1) · Brazil (1) · India (1)
David Russell, MD (2) · Bernhard G Landwehrmeyer, MD, PhD (1) · David H. Margolin, MD, PhD (1) · David Margolin, MD, PhD (1) · Francis O Walker, MD (1) · Frederick J Marshall, MD (1) · Huafang Li, Doctor (1) · Hufang Li, Doctor (1)
PMID 29480210, PMID 32250312, PMID 36463457, PMID 38489195, PMID 24878825, PMID 25223836, PMID 27072954, PMID 27434297, PMID 29725840, PMID 31059641, PMID 31381524, PMID 38058356, PMID 38615323, PMID 38988035, PMID 39027419, PMID 40235521, PMID 41188963, PMID 42032152
2015 (2), 2014 (1), 2016 (1), 2025 (1)